Back to news

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

PR Newswire•16/11/2026•07:00 ET
0

Key Highlights

  • ➤EXACT study dosed first two patients; mid-2027 topline data expected
  • ➤EXPRESS study IND cleared; first nmADPKD patient expected in Q3 2027
  • ➤Cash and equivalents $56.3 million at September 30, 2026
  • ➤Q3 net loss $5.5 million, or $0.49 per share
  • ➤Cash expected to fund operations into 2028

Expert Statements

Sumit Aggarwal, President and Chief Executive Officer of Eloxx Pharmaceuticals

“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease”

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update PR Newswire

* Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expected in mid-2027 * Finalized protocol and received IND clearance for Phase 2 EXPRESS study of exaluren in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD); first patient expected to be dosed in the third quarter of 2027 * Expanded leadership team with appointment of T.R. Srinivas, M.D., as SVP, Chief Medical Officer * Cash and cash equivalents of $56.3 million as of September 30, 2026 ARLINGTON, Mass., Nov. 16, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in